|
|
| | Dehydrocorydaline nitrate Basic information |
| Product Name: | Dehydrocorydaline nitrate | | Synonyms: | 5,6-Dihydro-2,3,9,10-tetramethoxy-13-methyldibenzo[a,g]quinolizinium nitrate;Dehydrocorydaline nitrate;Dehydrocorydaline nitrate USP/EP/BP;Hydrocortisonenitrate;Dehydrocorydaline nitrate, 10 mM in DMSO | | CAS: | 13005-09-9 | | MF: | C22H24NO4.NO3 | | MW: | 428.44 | | EINECS: | | | Product Categories: | | | Mol File: | 13005-09-9.mol |  |
| | Dehydrocorydaline nitrate Chemical Properties |
| Melting point | approximate 240℃ (dec.) | | storage temp. | Hygroscopic, -20°C Freezer, Under inert atmosphere | | solubility | Chloroform (Slightly), Methanol (Slightly) | | form | Solid | | color | Yellow to Dark Yellow | | Stability: | Hygroscopic |
| | Dehydrocorydaline nitrate Usage And Synthesis |
| Uses | Dehydrocorydaline nitrate (13-Methylpalmatine nitrate) is an alkaloid. Dehydrocorydaline regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates PARP[1]. Dehydrocorydaline nitrate elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities.[2]. Dehydrocorydaline nitrate shows strong anti-malarial effects (IC50=38 nM), and low cytotoxicity (cell viability>90%) using P. falciparum 3D7 strain[3]. | | target | IL Receptor | | References | [1] Xu Z, et al. Dehydrocorydaline inhibits breast cancer cells proliferation by inducing apoptosis in MCF-7 cells. Am J Chin Med. 2012;40(1):177-85. DOI:10.1142/S0192415X12500140
[2] Yoo M, et al. Dehydrocorydaline promotes myogenic differentiation via p38 MAPK activation. Mol Med Rep. 2016 Oct;14(4):3029-36. DOI:10.3892/mmr.2016.5653
[3] Nonaka M, et al. Screening of a library of traditional Chinese medicines to identify anti-malarial compounds and extracts. Malar J. 2018 Jun 25;17(1):244. doi: 10.1186/s12936-018-2392-4. DOI:10.1186/s12936-018-2392-4 |
| | Dehydrocorydaline nitrate Preparation Products And Raw materials |
|